Cleron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cleron

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Tablets, Oral suspension
Pharmacological class Macrolide Antibiotic
Common use Fighting Bacterial Infections
Origin Semi-synthetic (derived from Erythromycin)

What Type of Medicine is Cleron (Clarithromycin)?

Cleron is a prescription-only pharmaceutical product containing the active ingredient Clarithromycin, which is classified as a macrolide antibiotic. The drug functions as an antimicrobial agent that belongs to the second-generation macrolides, having been chemically derived from the older, naturally occurring Erythromycin compound. This semi-synthetic nature and specific chemical structure grant Clarithromycin key advantages, including stability in the stomach’s acidic environment, which improves its absorption and effectiveness after oral administration.

What is the General Purpose of This Macrolide Antibiotic?

The general purpose of Cleron is to combat active bacterial infections by inhibiting the growth and multiplication of susceptible organisms. The medicine works primarily as a broad-spectrum bacteriostatic agent, which limits the ability of pathogenic microorganisms to sustain themselves. This is achieved through targeted interference with the bacteria’s process of synthesizing essential proteins. The clinical benefit is seen in various settings, such as addressing common infections where the agent’s ability to achieve high concentrations in tissues, such as the lungs, is a characteristic of its activity. This action reduces the bacterial burden, providing the patient's immune system with the opportunity to successfully clear the infection.

What Forms of Cleron are Available for Oral Use?

Cleron is a single-ingredient product supplied in several pharmaceutical preparations designed for oral administration to different patient groups. These preparations include immediate-release and extended-release film-coated tablets suitable for adults, as well as granules for oral suspension, which are reconstituted into a liquid form. The provision of the oral suspension is a differentiating factor that ensures the active ingredient can be accurately and comfortably administered across all patient groups, notably including pediatric patients or those who may have difficulty swallowing solid forms.

Regulatory References

  1. Macrolides - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Cleron?

Possible Side Effects and Safety Information

The official safety profile of Cleron, containing the macrolide antibiotic Clarithromycin, is defined by adverse reactions classified into frequency categories and grouped by the affected System-Organ-Class (SOC) as documented in regulatory labeling.


Officially Documented Adverse Reactions

The most common adverse reactions (occurring in ge 1/100 to < 1/10 of patients) are typically related to Gastrointestinal disorders (including abdominal pain, diarrhea, nausea, and vomiting) and the Nervous system (including headache and dysgeusia, or taste perversion). Uncommon effects include conditions such as leukopenia, hypersensitivity, and hepatitis.


Serious Adverse Reactions and Safety Constraints

Official regulatory documents emphasize the risk of specific serious adverse reactions. These include rare but potentially fatal events involving the Cardiac system, such as QT prolongation which can lead to life-threatening arrhythmias including Torsades de pointes and ventricular tachycardia. Cases of fatal hepatic failure have also been reported, often in association with underlying conditions. Serious acute allergic reactions like anaphylaxis and Severe Cutaneous Adverse Reactions (SCAR) are also documented.

Safety limitations require that Clarithromycin is contraindicated in individuals with a known history of QT interval prolongation or ventricular arrhythmia, and those with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of the medicine. Furthermore, an increased risk of all-cause mortality has been observed one year or more after the end of a short treatment course in patients with stable Coronary Artery Disease (CAD), a pattern noted in official safety communications.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe a Cleron overdose primarily as an exacerbation of common gastrointestinal adverse reactions, leading to severe abdominal pain, vomiting, nausea, and diarrhea. Exposure to high doses has also been associated with reports of transient hearing loss.

Documented Severe Outcomes

Overdose carries a risk of potentially life-threatening complications affecting multiple physiological systems. The most serious outcomes documented in labeling include severe cardiac arrhythmias such as QT prolongation and Torsades de pointes, alongside significant hepatotoxicity (liver dysfunction).

Immediate Emergency Action Required

Regulators mandate that immediate medical attention must be sought if an overdose is suspected. Specifically, contact emergency services (e.g., 911) or a poison control center right away if the affected person has collapsed, experienced a seizure, is exhibiting trouble breathing, or cannot be awakened.

Management and Specific Risk

In the event of an overdose, no specific antidote is known. Management, as defined by regulatory authorities, relies on symptomatic and supportive treatment and measures to eliminate unabsorbed drug. Furthermore, regulatory documentation highlights that patients with severe renal impairment are at increased risk due to impaired drug elimination.

Therapeutic Uses of Cleron

Quick Facts

  • Primary Action: Assists in the management of bacterial infections.
  • Respiratory Support: Indicated for certain upper and lower respiratory tract infections.
  • Skin & Tissue: Utilized to address infections of the skin and soft tissues.
  • Gastrointestinal: May be included in regimens to help eradicate H. pylori bacteria, a factor in duodenal ulcer recurrence.
  • Dental Health: Demonstrates therapeutic action against certain dental infections, such as abscesses.

Cleron is a medication utilized in the therapeutic management of a variety of confirmed bacterial infections. Its use is indicated across several clinical domains, focusing on infections where susceptible organisms are present.

The medication is prescribed for individuals experiencing certain respiratory tract conditions, including infections affecting the throat, sinuses, and lungs. It is also an available option for addressing infections involving the skin and soft tissues. For patients with specific gastrointestinal concerns, Cleron is commonly included in combination therapy to reduce the risk of duodenal ulcer recurrence associated with the presence of Helicobacter pylori bacteria.

Furthermore, the treatment may be part of the regimen for certain ear and dental infections. Healthcare providers use Cleron as an established component in infection protocols, aiming to achieve a positive clinical response in patients who are diagnosed with these conditions. Individual response to treatment may vary.

Eligibility and Restrictions for Use

Contraindicated Populations (Must Not Use)

Cleron is contraindicated and must not be used by patients with specific pre-existing conditions or histories, as defined by official regulatory bodies. These absolute prohibitions include:

  • Known hypersensitivity to clarithromycin, erythromycin, or any other macrolide antibiotic.
  • A history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
  • A history of QT prolongation (congenital or acquired) or ventricular cardiac arrhythmia, including Torsades de Pointes.
  • Uncorrected electrolyte disturbances, such as hypokalemia or hypomagnesemia.
  • Severe hepatic failure in combination with renal impairment.

Age and Organ Function Restrictions

Eligibility rules apply to certain age groups and populations with organ impairment:

Category Eligibility Status (Regulatory Wording)
Pediatric Use Safety and efficacy have not been established in children younger than 6 months of age. The tablet formulation is not recommended for children under 12 years.
Renal Impairment Patients with severe renal impairment (Creatinine Clearance <30 mL/min) require a 50% dosage reduction.
Pregnancy/Lactation Use in pregnancy is not recommended unless no appropriate alternative therapy is available. The US label advises either discontinuing nursing or discontinuing the drug during treatment.
Myasthenia Gravis Use requires caution due to a reported risk of exacerbation or aggravation of the condition.

What should I know about interactions with other medicines?

Primary Pharmacokinetic Restrictions

Cleron's interaction profile is significantly defined by its classification as a strong inhibitor of the CYP3A4 enzyme, a major metabolic pathway. This pharmacokinetic mechanism can substantially increase the plasma concentrations of many co-administered medicines. The drug is also a documented inhibitor of P-glycoprotein, which contributes to increased exposure for substances like Digoxin.

Strictly Contraindicated Combinations

Several combinations are officially prohibited due to the high risk of serious adverse reactions. These strictly contraindicated co-administrations include medicines that prolong the QT interval, such as Pimozide and Cisapride, and the Ergot Alkaloids (Ergotamine, Dihydroergotamine), which carry a risk of acute toxicity. The use of potent HMG-CoA Reductase Inhibitors (Lovastatin, Simvastatin) is prohibited due to the elevated risk of rhabdomyolysis. Additionally, Oral Midazolam and certain newer agents like Lurasidone are contraindicated due to the risk of drastically increased systemic exposure.

Other Significant Interactions and Constraints

  • Pharmacodynamic Effects: Use with oral anticoagulants, such as Warfarin, may potentiate the effects, resulting in significant elevations in the International Normalized Ratio (INR).
  • Administration Rules: The extended-release tablet formulation must be taken with food. Administration must be separated from Zidovudine by at least two hours.
  • Population Note: The risk of Colchicine toxicity is heightened and the combination is contraindicated in patients with existing renal or hepatic impairment.

Mechanism of Action

Inhibition of Pathogen Protein Synthesis

Clarithromycin's primary mechanism involves the reversible binding to the 50 S ribosomal subunit inside susceptible bacterial cells. This binding site, located on the 23 S ribosomal RNA, is essential for manufacturing proteins. By physically blocking the translocation of the growing peptide chain, the drug halts the entire protein synthesis pathway . This action ultimately arrests the growth and replication of the pathogenic organisms, resulting in a bacteriostatic effect, which limits the population size of the pathogenic load and allows host immune processes to proceed more effectively.


Targeted Intracellular Accumulation

A secondary, mechanistically significant aspect of the drug’s action is its ability to be actively taken up and concentrated within host immune cells known as phagocytes. These cells deliver the concentrated drug to the site of infection, effectively enhancing local drug exposure in deep tissues or against bacteria that live inside host cells. This mechanism promotes high localized concentrations of the agent, optimizing the exposure of bacteria in deep tissues to the drug’s inhibitory action.

Dosage and Administration Information

Cleron (Clarithromycin) is primarily administered via the oral route using immediate-release (IR) tablets, extended-release (ER) tablets, or granules for oral suspension. An intravenous (IV) infusion form is also approved in specific jurisdictions for use when oral administration is not feasible.

The dosing pattern is determined by the specific formulation. Standard IR tablets and the oral suspension are generally taken twice daily (every 12 hours) over a course typically ranging from 7 to 14 days. The ER tablets are dosed once daily, typically as a 1000 mg dose. Special administration rules apply to ensure proper usage: while the IR forms may be taken without regard to food, the ER tablets must be taken with food to ensure correct drug absorption.

Usage instructions also define population-specific administration guidelines. The oral suspension is utilized for pediatric patients (6 months and older), with the dose calculated based on the child's body weight. Furthermore, a 50% dose reduction is specified for adult patients with severe renal impairment (creatinine clearance < 30 mL/min) to prevent drug accumulation. The oral suspension must be shaken well before use, and ER tablets must be swallowed whole to preserve their function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cleron


Evidence for Use in Respiratory Tract Infections

Research on Cleron's use primarily involves short-term randomized controlled trials (RCTs) and scientific reviews that combine data from many studies. These trials were designed to compare Cleron's activity to other antibiotic agents or placebo. The studies were generally conducted during periods of increased symptom activity and research examined how symptoms evolved in the observed populations, which included adults and adolescents studied in the context of studying conditions like community-acquired pneumonia. The main outcomes studied included whether patients experienced clinical success (improvements in outcomes related to physical discomfort like fever or cough) and whether laboratory tests reported microbiological eradication of the confirmed bacteria.

The findings describe patterns observed in the studies over defined, short time intervals, often less than two weeks. Long-term effects are not fully established following the conclusion of short-term treatment for these infections. Follow-up durations were limited in many of the key trials. Furthermore, the overall evidence landscape is challenged by the fact that data show patterns related to increasing rates of antibiotic resistance among common respiratory pathogens, which can introduce variability in findings depending on the region and the specific organism being treated.


Evidence for Use in H. pylori Eradication

Cleron was studied for its application as a component of combination therapy regimens, most commonly a "triple therapy," designed to evaluate outcomes in the context of the Helicobacter pylori (H. pylori) bacteria in the stomach. The primary outcomes related to systemic or functional imbalance that research examined in these trials included the rate of H. pylori clearance, which is confirmed using follow-up tests several weeks after the treatment is completed.

A key limitation is that Clarithromycin resistance was observed in some studies to be a significant factor. Evidence quality varies across studies based on geographical location and the local prevalence of resistant strains. This means that while research provides insight into short-term changes in eradication rates, the certainty remains low regarding success when used without prior knowledge of the bacterial susceptibility.


Long-Term Studies and Extended Follow-up

Beyond evaluating acute infections, a specific area of research was studied for long-term outcomes following the use of Cleron. The studies monitored all-cause mortality and outcomes describing perceived discomfort or systemic imbalance such as major adverse cardiac events, tracked years after the short course of antibiotics.

The findings were mixed. One key trial follow-up was associated with a numerically higher rate of all-cause mortality in a very specific population (older adults with coronary heart disease) when tracked years later. However, subsequent, larger observational cohort studies designed to replicate this finding reported mixed or inconsistent findings. The long-term effects are not fully established, and a precise mechanism that would explain a connection between a short-term antibiotic course and a long-term cardiac outcome is not understood.

Frequently Asked Questions (FAQ)

Common questions about Cleron (FAQ)


Q: Is Cleron considered a long-term medication?

A: Cleron is typically described as being for short-term use to treat specific infections. Official product information indicates that the usual course of treatment generally lasts between 7 and 14 days, depending on the condition being addressed. The medicine is not typically intended for continuous, chronic use.


Q: How quickly do the effects of Cleron typically start to be noticed?

A: Regulatory documents indicate that the active ingredient reaches its highest concentration in the bloodstream fairly quickly. Peak plasma concentrations are typically attained within 2 to 3 hours after the medicine is taken by mouth. The onset of perceived relief of symptoms is variable and is not the same as when the drug achieves its peak blood concentration.


Q: Is it common to feel tired when first starting Cleron?

A: Official safety documents list headache as a common adverse reaction associated with the use of this medicine. While not always common, regulatory bodies have also received reports of extreme tiredness or fatigue from post-marketing surveillance, which may affect a person's general energy levels.


Q: Can Cleron be used by people who have mild kidney problems?

A: Official guidance specifically addresses patients with severe renal (kidney) impairment, requiring a dosage reduction for those with a creatinine clearance less than 30 mL/ min. A person's healthcare provider assesses the appropriate use, and no universal restriction for mild cases is specified in the regulatory text.


Q: What is the difference between Cleron and similar drugs I've heard about?

A: Cleron contains the active ingredient clarithromycin, which is officially classified as a semi-synthetic macrolide antibiotic. Regulatory classification notes that it is derived from the older macrolide drug, erythromycin, and belongs to the second generation of this antibiotic class.


Q: Do I need to stop using Cleron gradually, or can I stop suddenly?

A: Official patient guidance emphasizes that the full prescribed course of treatment is completed to address the infection. Discontinuation guidance should be discussed with a healthcare provider, and instructions on gradual tapering are not usually provided in the regulatory information.


Q: What happens if I miss a planned use of Cleron?

A: General official advice suggests that if a use is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled use, the guidance states that the missed one should be skipped. Regulatory documents state that using a double amount to make up for a missed amount is not recommended.


Q: Is Cleron safe to use if I am driving or operating machinery?

A: Due to the potential for effects on central nervous function, such as dizziness or confusion, regulatory guidance states that caution should be exercised regarding driving or operating machinery until individual response is known. This is a standard warning associated with the medicine.


Q: How does Cleron affect a person's mood or energy levels?

A: Adverse reactions reported in official summaries include effects on the central nervous system, such as headache, dizziness, and confusion. These documented effects may potentially influence a person's general feeling or energy levels during the course of use.


Q: How does Cleron compare to older treatments for the same condition?

A: Cleron is classified as a second-generation macrolide, a type of antibiotic. This designation indicates it is a more recently developed, semi-synthetic derivative of older compounds, such as the first-generation macrolide, erythromycin.


Q: Is Cleron available as a generic version?

A: Yes, official drug product databases confirm that the active ingredient in Cleron, clarithromycin, is available in generic formulations. These generic versions contain the same active ingredient and adhere to the same regulatory standards as the original product.


Q: Are there official warnings about using Cleron with herbal supplements?

A: Official documentation advises that all co-administered medicines, including herbal products, vitamins, and minerals, are disclosed due to the potential for interactions. This general caution is given because the drug can influence the processing of other substances in the body.


Q: How long does Cleron stay in the body after the last use?

A: The elimination of the active compound from the body is tracked by regulatory science using a measure called the half-life. For a standard 500 mg use, official pharmacokinetics data indicates that the elimination half-life of the main compound is approximately 5 to 7 hours.


Q: Does Cleron have a risk of dependence or addiction?

A: Regulatory safety documentation for this macrolide antibiotic contains no official warnings or classifications regarding a potential for dependence, abuse, or addiction. The drug is not classified as a controlled substance in the context of dependence risk.


Q: Can using alcohol while on Cleron be dangerous?

A: Official patient information generally notes that alcohol is not known to directly reduce the effectiveness of the antibiotic. Regulatory bodies typically indicate that avoiding alcohol is commonly advised during treatment for infection to support a person's general recovery.


Q: Are there any known interactions between Cleron and certain vaccines?

A: Official drug interaction checkers confirm that Cleron should be avoided with certain live bacterial vaccines, such as the live typhoid vaccine. This restriction is in place to prevent the antibiotic from potentially interfering with the vaccine's ability to trigger an effective immune response.


Q: Why is Cleron sometimes mentioned in medical news?

A: The medicine has been the subject of official regulatory communications. For example, an FDA safety alert was issued concerning the use of the drug in patients with stable coronary heart disease due to a reported increased rate of all-cause mortality tracked years after treatment was concluded.


Q: Can the effectiveness of Cleron be impacted by other medical conditions I have?

A: Yes, official warnings indicate that pre-existing medical conditions can affect the drug. For instance, resistance patterns in the bacteria being treated or severe underlying conditions like kidney or liver impairment and specific heart conditions (QT prolongation) can influence a person's eligibility or the need for caution.


Q: Does Cleron cause sun sensitivity or skin issues?

A: Official safety sections specifically list the risk of Severe Cutaneous Adverse Reactions (SCAR) as a rare but severe risk. However, general sun sensitivity (photosensitivity) is not explicitly listed among the common or serious adverse reactions in the core regulatory summaries.


Q: Does Cleron affect birth control pills?

A: Official patient guidance from national health bodies states that Cleron does not typically reduce the effectiveness of hormonal contraception. However, if severe gastrointestinal side effects such as vomiting or persistent diarrhea occur, the protection offered by contraceptives may be reduced.


Q: What information is available regarding Cleron's safety during pregnancy?

A: Official documents from regulatory agencies state that use during pregnancy is not recommended unless no appropriate alternative is available. This warning is based on data, including animal studies, that suggested the potential for adverse effects on the fetus.


Q: Are there any known interactions between Cleron and common pain relievers?

A: The medicine is documented as a strong inhibitor of the CYP3A4 enzyme, a common mechanism for drug interactions. This means Cleron can affect the way many other co-administered medicines, including certain non-prescription pain relievers, are processed by the body.

How should Cleron be stored and disposed of?

Cleron must be stored according to regulatory requirements to maintain its stability and effectiveness, with specific instructions for both tablets and the oral suspension.

Cleron Tablets

The tablets should be stored at 20 C to 25 C (Controlled Room Temperature), protected from light and moisture, and kept in their tightly closed original container.

Cleron Oral Suspension

The reconstituted liquid suspension must be stored at room temperature (15 C to 30 C) and must not be refrigerated or frozen. The liquid is stable for 14 days after mixing and must be discarded after this period.

General Requirements and Disposal

All forms of Cleron must be kept out of the reach of children. Unused or expired medication should be disposed of using a drug take-back program. If one is unavailable, the product must be mixed with an undesirable substance, sealed, and placed in household trash, but not flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cleron found in:

A-Z Index: